A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

April 20, 2009

“Quad” HIV Pill Enters Phase II Study

Gilead Sciences Inc. announced today it initiated a Phase II study of a new four-in-one—or “Quad”—HIV treatment. The Quad pill includes Gilead’s experimental integrase inhibitor called elvitegravir, an experimental boosting agent called GS 9350 and the approved drugs Viread (tenofovir) and Emtriva (emtricitabine).

The study will enroll 75 HIV-positive people who’ve never taken antiretroviral therapy before and will randomize them to take either the Quad pill or Atripla (efavirenz, tenofovir and emtricitabine). The 48-week trial will determine both the efficacy and the safety of the Quad pill after 24 and 48 weeks of treatment.

The study is not so much to evaluate the efficacy and safety of elvitegravir—which has already successfully completed a Phase II study and is now in two large Phase III studies—as much as to test the new blood level boosting agent GS 9350, which is being examined as an alternative for low-dose Norvir (ritonavir).

Search: Quad pill, elvitegravir, GS9350, integrase inhibitor, booster, Norvir, ritonavir, Viread, tenofovir, Emtriva, emtricitabine, Atripla, efavirenz, Gilead Sciences


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 4 (of 4 total)    

christina l diamond, kewaskum, wi, 2009-05-25 21:55:08
i hope it helps alot of people!!!

Tim Horn, AIDSmeds.com, New York, NY, 2009-04-24 15:29:52
pablo - this is essentially a single pill containing four drugs, arguably easier to take than handfulls of pills. Please understand that it's just now going into intermediate studies, so we can't so much about its safety or effectiveness.

pabloMontagna, Newport Beach, CA, 2009-04-24 14:27:29
Don't TeASE ME... your article “Quad” HIV Pill Enters Phase II Study is stingy. Tell me what is it for, how is it better, why its been tested, Who is it conna help. How does it interact against virus?(simple wording) What are "they" looking to accomplish? Why? C'mon guys of POZ.. give us the whole enchilada man!!

RJ, Orange County CA, 2009-04-21 13:08:05
I can't help but notice that I don't see any PIs except for Norvir (the booster.) I have become resistant to all nukes and non-nukes over the past 25 years. I guess this wouldn't work for me. Boo.

comments 1 - 4 (of 4 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    ht2988
    Kalamazoo
    Michigan


    Luvlyfe27
    Huntsville
    Alabama


    racine
    New York
    New York


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.